Novel therapeutic agents in Waldenström's macroglobulinemia.
Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström's macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and histone deacetylase inhibitors. In this review, we summarize the current understanding of the clinical development of these agents in WM.
Ghobrial
Irene M
IM
Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA. irene_ghobrial@dfci.harvard.edu
Leleu
Xavier
X
Azab
Abdel Kareem
AK
Runnels
Judith
J
Jia
Xiaoying
X
Ngo
Hai
H
Melhem
Molly
M
Azab
Feda
F
Sacco
Antonio
A
Quang
Phong
P
Burwick
Nicholas
N
Moreau
Anne-Sophie
AS
Husu
Emanuel
E
Farag
Mena
M
Roccaro
Aldo
A
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors